|
Development of a population pharmacokinetic (PPK) model of intravenous (IV) trastuzumab in patients with a variety of solid tumors to support dosing and treatment recommendations. |
| |
Whitney Paige Kirschbrown |
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Roche |
| |
|
|
Consulting or Advisory Role - Certara Inc |
Travel, Accommodations, Expenses - Certara Inc |
| |
|
|
|
Stock and Other Ownership Interests - InSightec; Roche |
| |
|
|
Consulting or Advisory Role - Certara Inc |
| |
|
No Relationships to Disclose |
| |
|
Employment - Acerta Pharma (I); Genentech; Gilead Sciences (I) |
Stock and Other Ownership Interests - AstraZeneca (I); Gilead Sciences (I); Lilly (I); Roche |
Consulting or Advisory Role - Polaris Consulting (I) |
| |
|
|
Stock and Other Ownership Interests - Roche |